The US Food and Drug Administration (FDA) has cleared the first noninvasive multichannel brain neuromodulation system to treat acute migraine pain. The Relivion system, from Neurolief, is an adjustable headset that delivers modulated pulses of electric current through adaptive output channels around the head to six branches of the occipital and trigeminal nerves. It is Cloud-enabled and linked to a mobile phone app. The device is designed to learn over time and to provide personalized therapy for individual patients, the company says.
Latest posts made by Debjaan
FDA Clears Neuromodulation Device for Acute Migraine Pain
RE: Deprived of Sleep, Many Turn to Melatonin Despite Risks
@niyam While melatonin doses typically range from 1 to 5 milligrams, bottles examined have been off target with much more or less hormone in the product than listed on the label. Researchers from the University of Guelph in Ontario, Canada, tested 30 commercially available formulas and found the melatonin content varied from the ingredients labeled on the bottles by more than 10%. In addition to melatonin, the researchers found other substances in the bottles too: In about a quarter of the products, they also identified another chemical messenger called serotonin.
RE: Genetics of Acute Myeloid Leukemia?
@athu Testing for key genetic markers in patients with AML is important for both prognostic and treatment purposes. Generally, the relatively slow turnaround time for cytogenetic and molecular testing makes it difficult to tailor the initial induction based on these factors. However, the choice of consolidation and/or maintenance therapy can often benefit from risk stratification using genetic information. Treatment decisions have been made using this information in one of two ways: in deciding on the aggressiveness of treatment, and in determining whether targeted therapy may influence the genetic or genomic aberration and specifically treat the individual’s tumor.
RE: Prognosis of Herpes Zoster infection?
@nusrat The rash usually resolves within 10-15 days. The prognosis for younger and otherwise healthy patients is excellent. Elderly people have a significantly increased risk of complications. It rarely causes fatalities in patients who are immunocompetent, but it can be life-threatening in severely debilitated or immunocompromised patients. Disseminated zoster in immunocompromised patients can lead to death from encephalitis, hepatitis, or pneumonitis. Patients with active lymphoproliferative malignancies are at particular risk. Mortality rate from disseminated herpes zoster is between 5% and 15%.
RE: Got scratch from my vaccinated pet dog, what should I do?
@nibhriti Any dog scratch — including those that seem mild and harmless — ought to be treated immediately to prevent infection and other health complications. Consider the following steps: first, wash (but don’t scrub) the dog scratch wound with warm water and soap. Rinse for at least 5 minutes. Pat dry with a clean towel.
If the dog scratch is bleeding, apply pressure to the area with a clean gauze pad.
Apply an over-the-counter (OTC) antibiotic cream or ointment.
Cover the wound with a sterile bandage.